Digoxin pharmacokinetics in premature infants. 1982

A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou

An analysis of pharmacokinetic parameters of digoxin was carried out in six premature infants after the administration of a single total digitalizing dose of 20 microgram/kg. The data was analyzed using both a 2 and 3 exponential model. In the premature infant, the plasma half-life of digoxin is prolonged, while the volume of the central compartment, total body clearance, volume of distribution and volume of distribution at steady state are reduced compared to other aged patients.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
January 1962, Pediatrics,
A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
December 1979, The Journal of pediatrics,
A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
April 1979, The Journal of pediatrics,
A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
January 1977, Clinical pharmacokinetics,
A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
January 1985, Pediatric pharmacology (New York, N.Y.),
A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
September 2019, Journal of perinatology : official journal of the California Perinatal Association,
A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
January 1982, Developmental pharmacology and therapeutics,
A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
January 1986, European journal of clinical pharmacology,
A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
April 1983, The New England journal of medicine,
A R Hastreiter, and R L Simonton, and R L van der Horst, and R Benawra, and H Mangurten, and G Lam, and W L Chiou
January 1984, Pediatric pharmacology (New York, N.Y.),
Copied contents to your clipboard!